#1Omni Ab OmniAb, Inc. Nasdaq: OABI August 10, 2023 MNM 010N 1010101 NOIOL Y H 010 101010 010#2Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected cash runway, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, our technology platform and other technologies, our expectations regarding the addressable markets for our technologies, including the growth rate of the markets in which we operate, the timing of the initiation or completion of preclinical studies and clinical trials by our partners, expectations regarding product approvals and potential for future revenue growth, launches by our partners and the timing thereof, the anticipated introduction of new technologies and innovations and enhancement of our technology stack, the continued innovation around and the expected performance of our technologies and the opportunities they may create, the ability to add new partners and programs, and the potential for and timing of receipt of milestones and royalties under our license agreements with partners, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," “should," "expect,” “plan," "anticipate,” “could,” “intend," "target," "project," "contemplates,” "believes,” “estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: our future success is dependent on acceptance of our technology platform by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain, risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; regulatory developments in the United States and foreign countries; unstable market and economic conditions, including adverse developments with respect to financial institutions and associated liquidity risk, may have serious adverse consequences on our business, financial condition and stock price; we may use our capital resources sooner than we expect; and other risks described in our press releases and filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made, and except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Information regarding partnered products and programs comes from information publicly released by our partners. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about the antibody industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. 2 OmniAb#3Our Business LEVERAGING OUR PROPRIETARY DISCOVERY TECHNOLOGY PLATFORM WORLDWIDE dT Td Technology Offering Addresses Most Critical Challenges of Discovery Create, Screen, Deliver antibodies leveraging industry's only 4-species platform with differentiated tech and core competencies Leading and Proven Technology 74 partners have access to OmniAb antibodies 305 active programs with 3 product approvals Sources: Clarivate Analytics Cortellis database. POISED FOR GROWTH TO MEET A GLOBAL INDUSTRY NEED One of the Largest Greenfields in the Pharma Industry $279 billion total addressable market for antibodies by 2025 Innovation and Intelligent Expansion of Our Technology New technology launches in 2023 - OmniDeep™M, OmnidAb™ 3 prilic OmniAb#4Mission Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. OmniAb#5Antibodies and Industry Demand HIGHER CLINICAL SUCCESS RATES FOR ANTIBODY MEDICINES DRIVE OUR INDUSTRY'S NEED FOR DISCOVERY TECHNOLOGY Increasing Antibody Market ● $279B in antibody sales by 2025 (up from ~$238B in 2022) 51 blockbuster antibodies in 2022 5 best-selling antibodies had ~$75B of sales in 2022 Higher Success Rates Type of Drug Small Molecules Antibodies Clinical Success Rates (1) 7.5% 12.1% Historical success rates for antibodies are significantly higher than small molecules Acceleration of Regulatory Approvals (FDA and EMA) 70 60 50 40 30 20 10 0 Substantial growth in number of new antibody therapeutics Pre-2000 2001-2010 2011-2020 Sources: Clarivate Analytics Cortellis database. Tables of approved mAbs and antibodies in review available at: https://www.antibodysociety.org/resources/approved-antibodies/ (1) Defined as composite success rate of clinical development from Phase I trials to Approval, data from 2011-2020. Source: BIO | QLS Advisors | Informa Feb 2021 Report. LO 5 OmniAb#6Growth of Partner Programs PROGRESSION AND PERFORMANCE IN PROGRAMS BY STAGE OF DEVELOPMENT 21 Active Programs as of 2016(1) Preclinical: 1 Discovery: 20 (1) Estimated at the time of acquisition of OMT, Inc. 305 Active Programs as of 06/30/2023 Preclinical: 15 Phase 2: 2 Phase 1: 22 Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and future approvals Phase 3: 1 BLA: 1 Approved: 3 Discovery: 261 6 OmniAb#7Performance Indicators SIGNIFICANT GROWTH IN ACTIVE PARTNERS AND ACTIVE PROGRAMS ● 4 new license agreements signed in Q2 New platform license agreements with Merck & Co. Inc., Neurocrine Biosciences Inc., Stanford University, and Seattle Children's Hospital ● Strong annual growth in key performance indicators continues, net of attrition - Active Partners:(1)~18% CAGR 2016 through 2022 Active Programs:(2) ~25% CAGR 2016 through 2022 • Metrics position our business for growth 80 70 60 50 40 30 20 10 Number of Active Partners 2016 2017 2018 2019 2020 2021 2022 6/30/2023 350 300 250 200 150 100 50 (1) Represents the unique number of partners that have an active program or have executed a license agreement in advance of initiating an active program. (2) Represents programs for which research work has commenced or an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized. Number of Active Programs 2016 2017 2018 2019 2020 2021 2022 6/30/2023 7 OmniAb#8Select OmniAb Partners >70 COMPANIES CURRENTLY HAVE ACCESS TO OMNIAB ANTIBODIES AMGEN GigaGen A Grifols Company MERCK sanofi Boehringer Ingelheim gloria*** BIOSCIENCES Y/'s NEUROCRINEⓇ BIOSCIENCES symphogen a Servier Company 1361 基石药业 CSTONE PHARMACEUTICALS J Janssen ONO ONO PHARMACEUTICAL CO.,LTD. Takeda Genmab Merck 2 Pfizer Wuxi Biologics Global Solution Provider 8 OmniAb#9Performance Indicators ACTIVE CLINICAL PROGRAMS AND APPROVED PRODUCTS • 2 new programs entered the clinic in Q2 - IMVT-1402 (Immunovant): Next-generation FcRn antagonist GLS-012 (Gloria): anti-LAG-3 ● ● 3 new programs have entered the clinic so far in the first half of 2023 Based on dialog with our partners, we see potential for 1-2 additional new entries into clinical development for novel OmniAb- derived antibodies in the second half of 2023 Partner progression also showing the flexibility of our platform, with an increasing number of formats and modalities in clinical or preclinical development 30 25 20 15 10 5 Number of Active Clinical Programs and Approved Products J 2016 2017 2018 2019 2020 2021 2022 6/30/2023 9 OmniAb#10FcRn ● ● Q2 2023 and Recent Updates SELECT RECENT DEVELOPMENTS SHOW CONTINUED PARTNER MOMENTUM ● Batoclimab HARBOUR BIOMED HANALL>< BIOPHARMA IMMUNOVANT Immunovant is conducting advanced-stage studies in: generalized Myasthenia Gravis (gMG) (P3) Thyroid Eye Disease (P3) Chronic Inflammatory Demyelinating Polyneuropathy (P2b) Graves' Disease (P2) Harbour BioMed announced BLA acceptance of batoclimab for treatment of gMG in China HanAll announced progression towards initiation of a Phase 3 clinical study of batoclimab in gMG in Japan in 2023 FcRn ● IMVT-1402 Reference: Partner and Company disclosures HANALLX IMMUNOVANT BIOPHARMA Immunovant initiated a Phase 1 clinical trial of IMVT-1402 in healthy volunteers; expects Phase 1 data in second half of 2023 CSX-1004 Anti-fentanyl (and related synthetic opioids) ● CESSATION CD123 x CD3 -THERAPEUT CSI Cessation Therapeutics announced FDA authorization for First-in- Human clinical trial CSX-1004 is being developed for prevention of fentanyl overdose, which claimed more than 74,000 American lives last year Cessation expects to initiate trial in August APV0436 Aptevo™ Therapeutics Aptevo Therapeutics announced that APVO436, in combination with venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1B dose-escalation trial Aptevo intends to conduct two Phase 2 clinical trials to include relapsed/refractory AML patients beginning in the second half of 2023 and frontline patients beginning in the first half of 2024 GSK Program-1 Ion Channels and Transporters 10 GSK OmniAb, Inc. achieved a $2 million research progression milestone in Q2 for small molecule inhibitors of a genetically- validated target relevant to neurological diseases OmniAb#11The OmniAb Platform TECHNOLOGY OFFERING IS PAIRED WITH OUR HIGHLY SPECIALIZED AND EFFICIENT OPERATIONS Create Create Diverse Repertoires of High-Quality Antibodies Screen Screen Millions of Cells to Find Potential Therapeutic Candidates Deliver Further Characterize, Select & Optimize the Right Antibody We leverage our proprietary and differentiated technologies, rather than commoditized industry services that are widely available from CROS or built into big pharma 11 OmniAb#12The OmniAb Technology Offering TECHNOLOGY OFFERING ADDRESSES THE MOST CRITICAL CHALLENGES OF ANTIBODY DISCOVERY Technologies Create Create Diverse Repertoires of High-Quality Antibodies OmniRat OmniChicken OmniMouse Robust Antibodies for Any Target Omniflic Omni Clic Bispecific Antibody Computational Antigen Design & Proprietary Reagents Generation OmniTaur Cow-inspired Antibodies for Difficult Targets Screen Screen Millions of Cells to Find Potential Therapeutic Candidates xploration High-Throughput Single Cell Screening Gel Encapsulated Microenvironment (GEM) Single Cell Screening Ⓡ ● ● 0000 0000 Deliver Further Characterize, Select and Optimize the Right Antibody Custom Bioinformatics Next Generation Sequencing (NGS) Hit Expansion ● ICAGEN ION CHANNEL TECHNOLOGY ● ● Comprehensive Functional Characterization Proprietary lon Channel Assays STR: FC-Silencing Technology* STR of silico for and that are woven our various and Includes structural OmniDeep Sting, large multi-species antibody databases, molecular dynamics simulations, Al, and machine and deep learning sequence models, and more *OmniAb entered into an agreement with mAbsolve Ltd. for STR, mAbsolve's Fc-silencing platform technology, which provides OmniAb with exclusive, sublicensable right to incorporate the STR technology with antibodies that have been generated using OmniAb's antibody discovery platform. 12#13What is Biological Intelligence ™M? ● We believe that antibodies generated in vivo are superior to ones from other sources because they are naturally optimized through an iterative process that preferentially selects for antibodies with excellent specificity and developability profiles The ability of the immune system in our engineered transgenic animals to create optimized antibodies for human therapeutics is what we call Biological Intelligence ● • We believe this approach increases the efficiency and probability of success of therapeutic antibody discovery and may help limit the attrition of antibody product candidates in the clinic 13 OmniAb#14The OmniAb Platform Antibody Generation Technologies Computational Antigen Design & Proprietary Reagents OmniRat OmniMouse OmniChicken OmniFlic OmniClic OmniTaur™ Bispecific Antibody Cow-inspired Antibodies for Difficult Targets Generation Create Screen Deliver We believe generating large and diverse repertoires of high-quality antibodies increases the likelihood of discovering the antibody with the most desirable therapeutic characteristics Industry's only 4-species platform 3 approved and increasing number of clinical-stage antibodies A rich heritage of genetic engineering advancements Carefully designed transgenes for robust response Bispecific and cow-inspired technologies enable next-generation therapeutics 14 OmniAb#15Rodent Platforms ● ● ● Endogenous lg genes inactivated Expression of full human V gene diversity Streamlined conversion into fully human molecule Well-validated transgene design utilizes rodent constant regions for robust immune responses from the B-cell repertoire Geurts et al. Science 2009 Ménoret et al. Eur J Immunol 2010 Osborn et al. J. Immunol. 2013 VL Light chain loci CL Fully human LC VJ C mRNA ţ OmniRat* mniMouse + ОЮП VDJ C VH Heavy chain locus DH JH EuCuCy1 Cy2b εα HHHHH▬▬▬▬▬▬▬ Rat constant Human V, D, J Easy conversion Human Antibody 15 OmniAb#16Chicken Platforms: Powered by Evolution PRIMORDIAL TARGET GENE Early form of gene prior to avian/mammalian evolutionary split Ching et al. MAbs 2018 GREATER EVOLUTIONARY DISTANCE YIELDS GREATER IMMUNOGENICITY AND MORE ANTIBODY DIVERSITY O 300 MILLION YEARS AGO AVIAN LINEAGE MAMMALIAN LINEAGE OmniChicken OmniClic O ~95 MILLION YEARS AGO HUMAN ORTHOLOGUE MURINE ORTHOLOGUE ||||||| CAMELID ORTHOLOGUE CHICKEN ORTHOLOGUE 16 OmniAb#17OmniTaur: Ultralong CDRH3 Create Novel Binding Domains UNIQUE STRUCTURAL FEATURES OF ULTRALONG H3 ANTIBODIES OmniTaur™ ● ● CDRH3 Human Cow Novel structure may enable targeting epitopes unreachable by standard antibodies Long H3 domains can be expressed on human VH framework, or alone as ~5kD Picobodies™ antigen glycans VL VH Knob Stalk Stanfield et al. Sci Adv 2020 CDRH3 17 OmniAb#18Common Light Chain Platforms for Bispecific Antibodies STANDARD IgG FORMAT TO DE-RISK DOWNSTREAM DEVELOPMENT* OmniFlic Rearranged IgVK3-15/JK1 JK2-5 IgKC -0000- Rearranged human VK3-15 light chain combined with diversifying heavy chain Common light chain for OmniFlic and OmniClic allows interchangeability between the platforms Simple reformatting from monospecific into bispecific for efficient production Bispecific IgG +Gera, Nimish. "The evolution of bispecific antibodies." Expert Opinion on Biological Therapy (2022) OmniClic "Germlining" human VK3-15 light chain combined with diversifying heavy chain Monospecific IgG 18 IgVK3-15/JK1 OmniAb#19Diverse Formats and Modalities of Preclinical and Clinical Molecules Duobody Ⓡ Fab-VHH ADAPTIR™ (IgG4 exchange) (Knob-in-hole) scFv-Fc-scFv YYXX IgG-Anticalin®Ⓡ TRAAC* IgG-scFv Fab-Fc/scFv- Fc-scFv * Toll-like Receptor Agonist Antibody Conjugate (Tallac Therapeutics/ALX Oncology) IgG Multispecific (incl. T cell engager) 48% ADC 4% Monospecific 48% IgG HexaBody® * 19 OmniAb#20Antibody Repertoires NUMEROUS OPTIONS AVAILABLE TO ADDRESS DIVERSE PARTNER OBJECTIVES Host OmniMouse OmniRat OmniChicken Omniflic OmniClic OmniTaur™ ● ● ● ● ● ● V genes Full human V gene diversity Choice of light chain isotype Full human V gene diversity Choice of light chain isotype Single framework VH3/VK3 or VH3/VL1 Full human VH gene diversity with non-diversifying VK3 Single framework VH3/non-diversifying VK3 Single framework VH4/VL1 ● ● ● ● ● ● ● Structural and immunological features Diverse V gene usage and mixed genetic backgrounds Diverse V gene usage and mixed genetic backgrounds Distinctive target recognition Evolutionarily divergent host system for robust immune responses Fixed light chain for bispecific applications Fixed light chain for bispecific applications Ultralong CDR-H3's for enormous structural diversity ● ● ● ● ● ● ● ● ● ● ● Benefits for therapeutics discovery and development Widely accessible and flexible workflows Industry standard Widely accessible and flexible workflows Extensive track record Diverse and new epitope coverage High homology targets Excellent physical properties Bispecific applications leveraging standard IgG format Diverse epitope coverage Excellent physical properties Ease of manufacturing Access cryptic epitopes Unique modalities (Picobodies ™M) Building blocks for multispecific molecules 20 OmniAb#21Screening Platforms Hybridoma Workflow B-cell Workflow Immunization Isolate B-cells Enrichment optional Fusion 00000 00000 00 00 00000 xploration 00000 00000 Screen 00000 0000 Omnib Create Expression Screen Validation Deliver shk ATGCTAGCAGT Sequence Single-cell NGS ‒‒‒‒‒‒ MA Technologies enable screening against difficult targets: GPCRs, ion channels and surface antigens Bioinformatics 21 Our powerful single B-cell screening technologies, xploration and GEM assay, bypass bottlenecks of hybridoma workflows Al-driven multi-parameter screening of tens of millions of cells in hours instead of weeks OmniAb#22The OmniAb Platform Our discovery teams are flexibly positioned to work closely with partners to identify the right antibody ● ● ● ● Data from multi-parameter screening and performance assays used in combination with bioinformatics NGS hit expansion to identify variant antibodies with improved characteristics High-throughput epitope binning and kinetics analysis, and target-specific functional assays Proprietary assays for ion channel and transporter targets Create Screen 0 Deliver 80 22 OmniAb#23Ion Channels and Transporters • lon channels are key components in a wide variety of biological processes that involve rapid changes in cells Present in all human cells and affect vital functions such as nerve transmission, muscle contraction, cellular secretory processes and fluid movement Have broad therapeutic applicability including neurologic and metabolic diseases, pain, cancers, infectious diseases, and many others Inside of cell Source: Ion Channels, Guide to Pharmacology lons Closed Ion Channel Open Ion Channel lons In the search for novel drugs, ion channels are viewed as high-value targets 23 Outside of cell Cell Membrane OmniAb#24Ion Channels and Transporters DIFFERENTIATED ION CHANNELS AND TRANSPORTERS DISCOVERY PLATFORM AT OMNIAB ● ● One of industry's most experienced teams of ion channel discovery experts Continuous expansion and development of cutting-edge technologies including high-throughput electrophysiology and compound screening assays, structure- based optimization leveraging cryo-EM and molecular dynamics, deep learning models, proprietary X-ray fluorescence, etc. Extensive bank of custom cell lines, reagents and assays designed to accelerate ion channel drug discovery and development K2P Kv K2P K₂3 Kv10-11 K,10 K₂9 K₂11 K,12 Kako? KCa CNGB CNGA Ka 1.5 Ca2 Ca¹ ca.3 K6 K₂2 Cav Kir Nav Nav TRPM TRPP TRPML TRPC ANKTM1 TRPV TRP Single Cell Line(s) Compound Screening Assays Figure does not reflect all ion channel or transporter families, disease variants, species orthologs or bespoke constructs generated to accelerate therapeutic candidate selection that are available at OmniAb, Inc. Collaborations for High-Value Targets GSK 2 Programs (both discovery stage) Neurological Diseases ● Roche 3 Programs (all discovery stage) 24 Neurodevelopmental & Neurodegenerative Diseases In addition to on-going Collaboration/ Service Revenue, the discovery-stage programs with these two partners have a potential to generate: $1 billion in milestones Royalties on future sales OmniAb#25Intellectual Property Advantage PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CAN CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL Over 300 patents issued worldwide ● • We maintain a broad intellectual property estate with multiple long duration patent families covering each major element of our technology platform • Licenses are structured so that royalties are linked to the patents for the antibodies discovered with OmniAb, thereby creating a lengthy coverage tail ~80 patent filings by our partners claiming an OmniAb-derived antibody as primary invention, with expiries up to 2042 Antibody Patent Applications Filed by Partners 80 60 40 20 O 2014 2015 2016 2017 2018 2019 2020 2021 2022 25 OmniAb#26Business Model OUR AGREEMENTS ARE STRUCTURED TO ALIGN ECONOMIC AND SCIENTIFIC INTERESTS WITH OUR PARTNERS License partnerships designed to include: ● ● ● Upfront/Access fees Potential Collaboration/Service revenue Milestones Royalties on commercial sales 26 OmniAb#27Illustrative Antibody Deal Structure Profile A Year 0 Collaboration/ Access Fees: ~$1M - $2M 5 10 Clinical & Regulatory Milestones: ~$10M - $20M 15 20 Royalties: ~Low Single Digits Potential IP Extension 25 Year 0 Collaboration/ Access Fees: ~$100k $500k Profile B 5 10 Clinical & Regulatory Milestones: ~$5M - $15M Notes: Deal Economics have evolved over time. Unique deal structures may also be used (e.g., equity stakes, risk-sharing, buy-in options, etc.). Not representative of Icagen lon Channel Technology deal structures. 15 20 Royalties: ~Mid Single Digits Potential IP Extension 25 27 OmniAb#28Q2 2023 vs. Q2 2022 Financial Results ($ Millions) License and milestone revenue Service revenue Royalty revenue Total revenues Research & development General & administrative Amortization of intangibles Other operating (income)/expense, net Total operating expenses Loss from operations Other income (expense) Loss before income taxes Income tax (expense) benefit Net loss Net loss per share, basic and diluted Shares used in diluted per share calculation Q2 2023 $ 4.3 2.5 0.2 6.9 14.1 8.7 3.4 0.1 26.4 (19.4) 1.3 (18.2) 3.4 ($ 14.7) $ (0.15) 99,493 Q2 2022 $ 2.3 4.7 0.1 7.2 $ 11.5 5.0 3.1 0.2 19.8 (12.6) 0.0 (12.6) 2.3 ($ 10.3) (0.12) 82,612 Table includes rounded figures. Please reference press release dated 8.10.2023 for more detailed information. Variance $ 2.0 (2.3) 0.0 (0.3) 2.7 3.7 0.3 (0.0) 6.6 (6.9) 1.3 (5.6) 1.1 ($ 4.5) 28 OmniAb#29Balance Sheet - June '23 vs December '22 June 30, 2023 in Millions ASSETS Current assets: Cash & investments Accounts receivable, net Other current assets Goodwill & intangible assets PPE & leases Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY A/P & accrued exp Contingent liabilities Deferred revenue Operating lease liabilities Deferred income taxes, net $ $ $ Stockholders' equity: Total liabilities and stockholders' equity $ Table includes rounded figures. December 31, 2022 103.1 $ 8.6 4.2 245.9 40.1 3.3 405.2 $ 10.7 $ 6.2 10.8 26.5 17.2 333.8 405.2 $ 88.3 30.3 6.4 251.2 41.5 3.5 421.2 12.1 8.1 12.5 25.8 21.3 341.4 421.2 Business is close to break-even cash flow Expect to end 2023 with slightly more cash than 12/31/22 cash balance Current cash balance and cash from operations expected to provide sufficient capital to fund operations for foreseeable future 29 OmniAb#30Quarterly Results ($ Millions) License and milestone revenue Service revenue Royalty revenue Total revenues Research & development General & administrative Amortization of intangibles Other operating (income)/expense, net Total operating expenses Income/(loss) from operations Other income (expense) Income/(loss) before income taxes Income tax (expense) benefit Net income/(loss) Table includes rounded figures. Q1 '22 $ 4.1 5.3 0.3 9.6 10.8 4.1 3.4 (0.4) 17.8 (8.2) 0.0 (8.2) 1.9 ($ 6.3) Q2 '22 $ 2.3 4.7 0.1 7.2 11.5 5.0 3.1 0.2 19.8 (12.6) 0.0 (12.6) 2.3 Q3 '22 $ 1.4 4.9 0.6 6.9 13.2 5.6 3.3 (0.2) 21.8 (14.9) 0.0 (14.9) 2.3 ($ 10.3) ($ 12.6) Q4 '22 $ 31.1 3.9 0.4 35.3 12.9 10.2 3.3 (0.1) 26.3 9.0 0.6 9.6 (2.8) $ 6.8 Q1 '23 $ 12.6 4.0 0.3 16.9 13.8 8.2 3.4 0.0 25.4 (8.5) 1.3 (7.1) 1.0 ($ 6.1) Q2 '23 $ 4.3 2.5 0.2 6.9 14.1 8.7 3.4 0.1 26.4 (19.4) 1.3 (18.2) 3.4 ($ 14.7) 30 OmniAb#31FY 2021 and 2022 Financial Results ($ Millions) License and milestone revenue Service revenue Royalty revenue Total revenues Research & development General & administrative Amortization of intangibles Other operating (income)/expense, net Total operating expenses Income/(loss) from operations Other income (expense) Income/(loss) before income taxes Income tax (expense) benefit Net income/(loss) Net income/(loss) per share, basic and diluted Weighted average shares outstanding $ FY21 $ 14.7 20.1 0.0 34.7 39.2 16.9 13.0 1.2 70.4 (35.6) 1.3 (34.4) 7.3 ($ 27.0) (0.33) 82.6 FY22 $38.9 18.8 1.4 59.1 48.4 24.9 13.0 (0.6) 85.7 (26.6) 0.6 (26.1) 3.7 ($ 22.3) $ (0.26) 85.3 Table includes rounded figures. Please reference press release dated 3/30/23 for more detailed information. Variance $ 24.3 (1.3) 1.4 24.3 9.1 8.0 0.1 (1.8) 15.4 9.0 (0.7) 8.3 (3.6) $ 4.7 31 OmniAb#32Share Information - as of 6/30/23 (in millions) Basic Share Count Total Earnout Shares RSU/Options/Warrants Employee Unvested RSU/PSU Employee Options Public/Private Warrants Total RSU/Options/Warrants Total Potential Shares 99.9 16.3 2.4 21.4 19.0 42.8 158.9 Basic Shares - Common Shares Outstanding/Public Float Earnout Shares - 50% vest at $12.50, 50% vest at $15.00 - VWAP of stock for 20 out of 30 consecutive - trading days at each respective level for vesting to occur Expire 11/1/27 Warrants Expire 11/1/27, $11.50 strike price 32 OmniAb#33Our Key Areas of Focus Going Forward WE BELIEVE WE ARE WELL-POSITIONED FOR FUTURE GROWTH WHILE WE MAKE AN ENDURING AND SIGNIFICANT IMPACT ON THE INDUSTRY AND GLOBAL HUMAN HEALTH We Leverage a Highly Scalable Business where Investments in Technologies and Innovation are Informed by Discovery Relationships with our Partners Partnered Pipeline Development, Expansion and Advancement Continued Workflow Versatility Initiatives Team: Strong culture; hire, develop, motivate the best Expanding the Reach of our Platform A FOCUS ON KEY STAKEHOLDERS IS AT OUR FOUNDATION 8 8 $8 Fu Partners: Focus on customer service and future needs \/ > Investors: Superior business execution to create value New Technology Development Community: Lead with integrity and responsibility 33 OmniAb#34Omni Ab For more information, please visit www.omniab.com#35Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline AS OF 06/30/2023 Partner gloria #ARCUS GILEAD Zimberelimab C Sugemalimab Teclistamab Batoclimab Tiragolumab GEN1046 M6223 APVO436 JNJ-70218902 JNJ-78306358 1351 Ins 基石药业 CSTONE Janssen th HANALL>< HARBOUR IMMUNOVANT Genentech A Member of Genmab BIONTECH Janssen Ichen MERCK Aptevo Janssen effles Genmab OCTTQ Capu symphogen a Servier Company Pfizer symphogen a Servier Company symphogen Servier Company abbvie AstraZeneca AMGEN SalubrisBio Zhilkang Hongyi Genmab CURON Boehringer Ingelheim Undisclosed Merck Janssen chan-plan BIONTECH Seagen HANALL><IMMUNOVANT gloria譽衡生物 Program GEN1047 S095017 S095018 S095024 S095029 ABBV-383 TNB-486 AMG 340 SAL003 Undisclosed CN1 Undisclosed Undisclosed M9140 GEN1053 JNJ-79635322 SGEN-BB228 IMVT-1402 GLS-012 Source Animal OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniMouse OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniFlic OmniFlic OmniFlic OmniRat OmniRat OmniRat OmniChicken OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat Therapy Area Oncology Oncology Oncology Immunology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Metabolic Oncology Oncology Undisclosed Gastrointestinal Oncology Oncology Oncology Oncology Immunology Oncology Target PD-1 PD-L1 BCMA x CD3 FcRn TIGIT PD-L1 x 4-1BB TIGIT CD123 x CD3 Undisclosed HLA-G x CD3 B7H4 x CD3 LAG-3 TIM-3 CD73 NKG2A BCMA x CD3 CD19 x CD3 PSMA x CD3 PCSK9 Undisclosed Undisclosed Undisclosed Undisclosed CEACAM-5 CD27 Undisclosed CD228 x 4-1BB FcRn LAG-3 Phase 1 Phase 2 Phase 3 Registration Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020 Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved and marketed in China. Teclistamab is approved and marketed in the US and EU with $35M launch milestones paid. Indicates program with fully paid license from OMT, Inc. prior to acquisition. Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics. Approved 35 OmniAb